Similarly, Nampt (FK-866) and Parp (olaparib) inhibition significantly reduced skin epithelial lesions in the psoriasis mutant (S5A–S5C Fig), which share the skin inflammation and keratinocyte hyperproliferation phenotypes with the Spint1a-deficient line but has a loss-of-function mutation in atp1b1a, which encodes the beta subunit of a Na+/K+-ATPase pump [36,37]. The gene discussed is PARP1; the disease is psoriasis.